KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Staar Surgical (STAA) Research & Development (2016 - 2026)

Staar Surgical's Research & Development history spans 17 years, with the latest figure at $9.2 million for Q1 2026.

  • For Q1 2026, Research & Development fell 5.39% year-over-year to $9.2 million; the TTM value through Jan 2026 reached $42.4 million, down 10.34%, while the annual FY2026 figure was $40.1 million, 11.61% down from the prior year.
  • Research & Development reached $9.2 million in Q1 2026 per STAA's latest filing, roughly flat from $9.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $13.7 million in Q1 2025 to a low of $6.9 million in Q4 2023.
  • Average Research & Development over 5 years is $10.4 million, with a median of $10.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: dropped 29.08% in 2023, then soared 40.73% in 2024.
  • A 5-year view of Research & Development shows it stood at $9.8 million in 2022, then decreased by 29.08% to $6.9 million in 2023, then surged by 40.73% to $9.8 million in 2024, then decreased by 5.75% to $9.2 million in 2025, then grew by 0.38% to $9.2 million in 2026.
  • Per Business Quant, the three most recent readings for STAA's Research & Development are $9.2 million (Q1 2026), $9.2 million (Q3 2025), and $10.3 million (Q2 2025).